• Helping those with life threatening diseases

  • Better medicine for aldehyde metabolism disorders

  • Guided by novel scientific research


home page

ALDEA Pharmaceuticals is developing a number of small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) superfamily to address significant unmet medical needs.

Latest News

"Targeting aldehyde dehydrogenase 2: New Therapeutic Opportunities" published in Physiological Reviews

Dr. Richard Shames joins ALDEA Pharmaceuticals as Chief Medical Officer

"Variant ALDH2 is associated with accelerated progression of bone marrow failure in Fanconi anemia patients" published in BLOOD